Entasis Therapeutics

$8.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (2.05%) Today
-$0.01 (-0.12%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ETTX and other stocks, options, ETFs, and crypto commission-free!

About ETTX

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. Read More The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.

Employees
33
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
111.25M
Price-Earnings Ratio
Dividend Yield
Average Volume
20.00K
High Today
$8.47
Low Today
$8.15
Open Price
$8.33
Volume
6.09K
52 Week High
$13.70
52 Week Low
$3.97

Collections

ETTX News

BenzingaJul 29

Entasis Therapeutics CEO: 'Our Antibiotics Work Differently'

21

ETTX Earnings

-$20.00
-$13.60
-$7.20
-$0.80
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$1.02 per share

More ETTX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.